local_hospital

Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego W Lodzi SPZOZ

Address
lock Available on a paid plan

Cardiovascular and Heart Failure Research

At Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego W Lodzi SPZOZ, a major focus is cardiovascular disease and heart failure, with studies spanning acute and chronic forms of the condition as well as related kidney and inflammatory complications. This work is aimed at testing new treatment approaches and improving outcomes for people living with complex heart disease.

  • Heart failure with preserved, mildly reduced, or reduced ejection fraction
  • Acute myocardial infarction and atherosclerotic cardiovascular disease
  • Cardiorenal disease, systemic inflammation, and treatment response

These trials explore whether new therapies can reduce hospitalizations, lower cardiovascular risk, and improve symptoms and heart function.

Kidney, Metabolic, and Inflammation-Linked Studies

Research at this hospital clinic also includes chronic kidney disease and conditions where kidney problems overlap with heart disease and high blood pressure. The studies are designed to evaluate whether emerging treatments can slow disease progression and better control inflammation-driven illness.

  • Chronic kidney disease with hypertension or systemic inflammation
  • Heart failure complicated by impaired kidney function
  • Inflammation-related cardiovascular and renal risk

Overall, this area of research is focused on finding safer and more effective ways to protect both kidney and cardiovascular health.

Respiratory and Lung Disease Trials

The site contributes to respiratory disease research, especially in chronic obstructive pulmonary disease and progressive pulmonary fibrosis. These studies aim to assess whether new therapies can reduce worsening symptoms, limit flare-ups, and preserve lung function over time.

  • Chronic obstructive pulmonary disease and chronic bronchitis
  • Progressive pulmonary fibrosis
  • Long-term symptom control and lung function preservation

This research supports the search for better treatment options in chronic lung conditions that can significantly affect daily life.

Immune-Mediated Skin and Muscle Disorders

Another important area is immune system disease, including inflammatory skin and muscle disorders. Trials here examine whether new therapies can improve disease control, reduce active inflammation, and support sustained remission in conditions that are often difficult to manage.

  • Bullous pemphigoid
  • Moderate-to-severe plaque psoriasis
  • Polymyositis and dermatomyositis

These studies are focused on testing treatment effectiveness and helping patients achieve better symptom relief and disease stability.

Neurology and Musculoskeletal Care

Clinical research at the site also extends to nervous system diseases and musculoskeletal disorders, reflecting a broad interest in conditions that affect movement, strength, and long-term function. The studies are intended to evaluate new options that may slow progression or improve recovery and quality of life.

  • Primary progressive multiple sclerosis
  • Total knee arthroplasty and prevention of venous thromboembolism
  • Musculoskeletal and neural functional outcomes

This line of research combines treatment innovation with practical goals such as better postoperative protection and improved disability management.

Site Overview

assignment
35
connected trials
corporate_fare
22
sponsors
science
64
IMPs

Activity Indicator

Last 6 months

3
Trials started
+200% vs previous period.
1
Trials started 6–12 months ago
35
Total trials linked
Highly Active
trending_upGrowing+200%
1
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 11 therapeutic areas and 15 of 64 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 52 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
16
Sponsors (total)
22
Active sponsors
13

Sponsor Network

Top 13 by active trials.

lock +12 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +5 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
35
Outperforms 91% of sites
public
Therapeutic diversity
11areas
Outperforms 96% of sites
groups
Sponsor diversity
22sponsors
Outperforms 92% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego W Lodzi SPZOZ

lock Showing 1 of 35 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 3, Multicenter, Randomized, Open-Label, Sponsor-Blinded, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX).Regeneron Pharmaceuticals Inc.Phase IIIRecruitingNov 2025

IMP list

lock Showing 1 of 64 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Ziltivekimab4Unknown2021-09-242024-08-01

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.